| 000 | 01862 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517144819.0 | ||
| 264 | 0 | _c20180425 | |
| 008 | 201804s 0 0 eng d | ||
| 022 | _a2051-1426 | ||
| 024 | 7 |
_a10.1186/s40425-017-0228-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLipson, Evan J | |
| 245 | 0 | 0 |
_aBasal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. _h[electronic resource] |
| 260 |
_bJournal for immunotherapy of cancer _c2017 |
||
| 300 |
_a23 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 |
_aB7-H1 Antigen _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aCarcinoma, Basal Cell _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGene Expression Regulation, Neoplastic _xdrug effects |
| 650 | 0 | 4 |
_aHedgehog Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLymphocytes, Tumor-Infiltrating _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 650 | 0 | 4 |
_aTumor Microenvironment _xdrug effects |
| 700 | 1 | _aLilo, Mohammed T | |
| 700 | 1 | _aOgurtsova, Aleksandra | |
| 700 | 1 | _aEsandrio, Jessica | |
| 700 | 1 | _aXu, Haiying | |
| 700 | 1 | _aBrothers, Patricia | |
| 700 | 1 | _aSchollenberger, Megan | |
| 700 | 1 | _aSharfman, William H | |
| 700 | 1 | _aTaube, Janis M | |
| 773 | 0 |
_tJournal for immunotherapy of cancer _gvol. 5 _gp. 23 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s40425-017-0228-3 _zAvailable from publisher's website |
| 999 |
_c27017848 _d27017848 |
||